Telemedicine in Eating Disorder Treatment: Systematic Review
Abstract
Background: Telemedicine has emerged as a promising tool to enhance adherence and monitoring in patients with eating disorders (EDs). Traditional face-to-face cognitive therapies remain the gold standard; however, integrating telemedicine may provide additional support and improve patient engagement and retention. Given the increasing use of digital health interventions, it is crucial to assess their safety and effectiveness in complementing conventional treatments.
Objective: We aimed to evaluate the safety and effectiveness of telemedicine as a complementary tool for cognitive face-to-face therapies to promote adherence and monitoring of patients with EDs.
Methods: We consulted the National Institute for Health and Care Excellence, the Canadian Agency for Drugs and Technologies in Health (now known as Canada's Drug Agency), MEDLINE (Ovid), Embase, Web of Science, Cochrane Library, international HTA database (International Network of Agencies for Health Technology Assessment), CINAHL (EBSCO), and PsycINFO (EBSCO) websites and databases in December 2024 to identify eligible systematic reviews, synthesis reports, or meta-analyses that address telemedicine as a complementary therapy to face-to-face care in patients with EDs. Two researchers performed an independent critical reading of the systematic reviews and assessed the risk of bias using AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews, version 2).
Results: We initially identified 1004 studies, but only 5 (0.5%)…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.